Menora Mivtachim Holdings LTD. lifted its position in shares of Eloxx Pharmaceuticals (OTCMKTS:ELOX) by 17.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,202,456 shares of the company’s stock after purchasing an additional 320,000 shares during the period. Menora Mivtachim Holdings LTD. owned 6.11% of Eloxx Pharmaceuticals worth $21,958,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. raised its stake in Eloxx Pharmaceuticals by 36.9% in the fourth quarter. BlackRock Inc. now owns 1,493,471 shares of the company’s stock worth $17,938,000 after buying an additional 402,501 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Eloxx Pharmaceuticals by 6.0% in the fourth quarter. Bank of New York Mellon Corp now owns 67,111 shares of the company’s stock worth $806,000 after buying an additional 3,800 shares in the last quarter. Geode Capital Management LLC raised its stake in Eloxx Pharmaceuticals by 10.0% in the fourth quarter. Geode Capital Management LLC now owns 237,986 shares of the company’s stock worth $2,858,000 after buying an additional 21,634 shares in the last quarter. Bank of America Corp DE raised its stake in Eloxx Pharmaceuticals by 226.0% in the fourth quarter. Bank of America Corp DE now owns 14,209 shares of the company’s stock worth $171,000 after buying an additional 9,851 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY raised its stake in Eloxx Pharmaceuticals by 356.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 10,172 shares of the company’s stock worth $122,000 after buying an additional 7,944 shares in the last quarter.

A number of research firms recently issued reports on ELOX. Canaccord Genuity reissued a “buy” rating and issued a $17.00 price target (down from $20.00) on shares of Eloxx Pharmaceuticals in a research note on Wednesday, May 15th. They noted that the move was a valuation call. SunTrust Banks decreased their price target on shares of Eloxx Pharmaceuticals to $10.00 and set a “buy” rating for the company in a research note on Thursday, August 8th. Finally, Zacks Investment Research downgraded shares of Eloxx Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday.

In related news, major shareholder Pontifax Management 4 G.P. (20 bought 200,000 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The shares were bought at an average price of $9.00 per share, for a total transaction of $1,800,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 44.03% of the company’s stock.

Shares of ELOX traded up $0.17 on Tuesday, hitting $6.58. 27,294 shares of the stock traded hands, compared to its average volume of 54,984. The firm has a 50 day simple moving average of $8.54. Eloxx Pharmaceuticals has a one year low of $5.14 and a one year high of $18.50.

Eloxx Pharmaceuticals (OTCMKTS:ELOX) last issued its earnings results on Wednesday, August 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.03).

Eloxx Pharmaceuticals Profile

Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations.

Featured Story: How does a 12b-1 fee affect fund performance?

Institutional Ownership by Quarter for Eloxx Pharmaceuticals (OTCMKTS:ELOX)

Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.